Treatment of TASC C and D Femoropoliteal Lesions with XXXX eluting Stents: 12 month Results of the STELLA-PTX Registry.

@entity1 @entity174 @entity75 @entity1311 @entity613 @entity715
OBJECTIVE: The aim was to evaluate the safety and the efficacy of primary stenting with @entity1311 eluting stents for TASC C and D femoropopliteal lesions. METHODS: @entity1 with TASC C/D de novo femoropopliteal lesions were treated by implanting @entity1311 eluting stents. @entity1 were included in a single center registry and prospectively followed by clinical and ultrasound evaluation. X-ray of the stented zone was systematically performed 12 months after implantation. The primary endpoint was primary sustained clinical improvement after 12 months. RESULTS: A total of 45 @entity1 (48 limbs) suffering from @entity613 (25 limbs) or CLI (23 limbs) were enrolled. Lesions were either TASC C (28 limbs) or TASC D (20 limbs). The mean length of the treated segment was 252      90  mm. The mean number of stents was 2.9      1 (2-5). Mean follow up was 12.7 months. No @entity1 was lost to follow up. At 1 year post procedure, primary and secondary sustained clinical improvements were 56.3      7.4% and 80.1      5.9% respectively. Freedom from @entity75 and target extremity revascularization were 63.6% and 90.1%, respectively. Primary and secondary patency rates were 52.5% and 79.6%. One year primary sustained clinical improvement rates for TASC C/D were 63.3      9.2% and 45.6      11.7%, respectively (p  =  .34). One year primary sustained clinical improvement rates for @entity613 /CLI @entity1 were 68      9.3% and 41.6      11.1%, respectively (p  =  .13). The incidence of in stent re-stenosis and in stent @entity715 were 25% and 14%, respectively. The incidence of stent @entity174 was 12.5% on a limb basis and 9% on a per stent basis. CONCLUSIONS: The @entity1311 eluting stent did not achieve its goal in terms of prevention of in stent re-stenosis for TASC C/D femoropopliteal lesions. It requires frequent re-interventions during the first year to maintain satisfactory clinical results.
